December 1, 2023The flagship product, Jiuwei Zhenxin Granules, a central nervous system medication developed by Beilu Pharmaceutical, has been included in the "Guidelines for the Diagnosis and Treatment of Ankyl...view
June 13, 2025Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) for its Iohexol Injection issued by Hungarian National Institute of Pharmacy and Nutrition (OGYÉ...view
June 26, 2025CPHI & PMEC China 2025 recently made a grand debut in Shanghai. This year's exhibition showcases the latest innovations and cutting-edge technologies across the entire pharmaceutical supply ch...view
March 22, 2024Recently, Beilu Pharmaceutical received the "Drug Supplementary Application Approval Notice" (Notice Number: 2024B01144) for Gadobenate Dimeglumine Injection issued by the National Medical P...view
March 22, 2022The integration of "APIs + Injection" is the key layout of Beilu Pharma (300016)'s strategic development in recent years, and the construction of contrast agent APIs is one of the compan...view
August 4, 2022Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...view